INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of GSK plc regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On July 17, 2025, GSK announced that the FDA Oncologic Drugs Advisory Committee voted against the benefit/risk profile of Blenrep at the proposed dosage, leading to a decline in GSK's ADR price by $1.81, or 4.73%, closing at $36.47 [2] - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3]